Financial incentive interventions for smoking cessation among Chinese smokers: study protocol for a cluster randomised controlled trial
BMJ Open · 2024
DOI: 10.1136/bmjopen-2023-080344 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift BMJ Open, 2024. Verfasst von Xiaochen Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Peking University Department of Social Medicine and Health Education, Beijing, Beijing, China. Hauptthemen laut MEDLINE: Smoking Cessation, Motivation. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Introduction There is an urgent issue to relieve the burdens caused by tobacco use through feasible and effective smoking cessation interventions, particularly in a middle-income country with less accessible smoking cessation services and high demand for quitting smoking. Financial incentives have shown effective in changing health behaviours, thus needing to test its portability to a wider implementation and effectiveness of increasing smoking cessation rates. Methods and analysis This is a three-arm cluster randomised controlled trial. 462 eligible participants will be assigned to 2 financial incentive groups—rewards or deposits, or the control group. All participants including those in the control group will receive text messages to help quitting smoking developed by the US National Cancer Institute over a 3-month intervention period. In addition to text messages, reward group participants will be rewarded with CNY200 and CNY400 (CNY100 approximately US$15) for sustained smoking abstinence at 1 month and 3 months follow-up assessments; participants in the deposit group will accumulate CNY200 and CNY600 in the deposit accounts after verified smoking abstinence at 1 month and 3 months follow-up assessments, and all the deposits will be given at once right after the 3-month follow-up visit. The primary outcome is biochemically verified smoking abstinence rate sustained for 6 months after enrolment. Ethics and dissemination This trial protocol has been approved by the Ethics Committee of Peking University Health Science Centre (date: 23 February 2023; ethical approval number: IRB00001052-22172). Results and findings of this trial will be disseminated in peer-reviewed journals and professional conferences. Trial registration number ChiCTR-IOR-2300069631.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Peking University Department of Social Medicine and Health Education, Beijing, Beijing, China.
- Brown University School of Public Health, Providence, UK.
- Department of Social Medicine and Health Education, Peking University, Beijing, China.
- Peking University Institute for Global Health and Development, Beijing, China.
- Department of Marketing, Tianjin University of Finance and Economics, Tianjin, China.
- Peking University Department of Social Medicine and Health Education, Beijing, Beijing, China changchun@bjmu.edu.cn.
ORCID-Profile: Xiaochen Yang, Omar Galárraga, Haoxiang Lin, Fei Cao, Chun Chang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Yang, X., Galárraga, O., Cao, W., Lin, H., Cao, F., & Chang, C. (2024). Financial incentive interventions for smoking cessation among Chinese smokers: study protocol for a cluster randomised controlled trial. BMJ Open. https://doi.org/10.1136/bmjopen-2023-080344
Vancouver
Yang X, Galárraga O, Cao W, Lin H, Cao F, Chang C. Financial incentive interventions for smoking cessation among Chinese smokers: study protocol for a cluster randomised controlled trial. BMJ Open. 2024. doi:10.1136/bmjopen-2023-080344
BibTeX
@article{Yang2024,
author = {Yang, Xiaochen and Galárraga, Omar and Cao, Wangnan and Lin, Haoxiang and Cao, Fei and Chang, Chun},
title = {Financial incentive interventions for smoking cessation among Chinese smokers: study protocol for a cluster randomised controlled trial},
journal = {BMJ Open},
year = {2024},
doi = {10.1136/bmjopen-2023-080344}
}
EUVIMED